Disease Progression and Staging in Progressive Supranuclear Palsy

Migration, Crosslink

📖

Disease Progression and Staging in Progressive Supranuclear Palsy

active

wiki page Created: 2026-04-02T07:19:56 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-psp-disease-progression-

📖 Wiki Page

mechanism3633 wordssynced 2026-04-02

Disease Progression and Staging in Progressive Supranuclear Palsy

Overview

Progressive supranuclear palsy (PSP) is a 4-repeat (4R) tauopathy characterized by relentless progression of neurological dysfunction. Understanding disease progression patterns is critical for clinical management, clinical trial design, and development of disease-modifying therapies. The disease typically manifests in mid-to-late adulthood, with a median survival of 5-9 years from symptom onset, making it one of the more rapidly progressive neurodegenerative disorders [1][2]. [@golbe2008a]

PSP belongs to the family of frontotemporal lobar degenerations (FTLD) with tau pathology (FTLD-tau) and shares clinical and pathological features with corticobasal degeneration (CBD) and argyrophilic grain disease (AGD). The characteristic neuropathological hallmark is the accumulation of 4R tau in neurons and glia, forming neurofibrillary tangles (NFTs), coiled bodies, and astrocytic tufts [3][4]. [@pagano2021]

Natural Disease Course

The clinical progression of PSP follows a relatively predictable pattern, though the rate of progression and specific symptoms can vary by clinical subtype. Understanding the natural history is essential for patient counseling, care planning, and clinical trial outcome measures. [@hglinger2017]

Preclinical Phase

The preclinical phase of PSP is increasingly recognized through biomarker studies. During this phase: [@mds2017]

...

Disease Progression and Staging in Progressive Supranuclear Palsy

Overview

Progressive supranuclear palsy (PSP) is a 4-repeat (4R) tauopathy characterized by relentless progression of neurological dysfunction. Understanding disease progression patterns is critical for clinical management, clinical trial design, and development of disease-modifying therapies. The disease typically manifests in mid-to-late adulthood, with a median survival of 5-9 years from symptom onset, making it one of the more rapidly progressive neurodegenerative disorders [1][2]. [@golbe2008a]

PSP belongs to the family of frontotemporal lobar degenerations (FTLD) with tau pathology (FTLD-tau) and shares clinical and pathological features with corticobasal degeneration (CBD) and argyrophilic grain disease (AGD). The characteristic neuropathological hallmark is the accumulation of 4R tau in neurons and glia, forming neurofibrillary tangles (NFTs), coiled bodies, and astrocytic tufts [3][4]. [@pagano2021]

Natural Disease Course

The clinical progression of PSP follows a relatively predictable pattern, though the rate of progression and specific symptoms can vary by clinical subtype. Understanding the natural history is essential for patient counseling, care planning, and clinical trial outcome measures. [@hglinger2017]

Preclinical Phase

The preclinical phase of PSP is increasingly recognized through biomarker studies. During this phase: [@mds2017]

Subtle cognitive changes: Executive dysfunction may be detectable on formal testing
Behavioral changes: Apathy and reduced initiative become apparent
Motor subtle signs: Mild postural instability and slowed saccades may be present
Biomarker changes: Elevated neurofilament light chain (NfL) in cerebrospinal fluid (CSF) and plasma [5][6]

The preclinical phase likely spans several years before the emergence of clinically manifest symptoms, similar to other neurodegenerative diseases. [@hglinger2017a]

Early Stage (Years 1-3)

The early stage of PSP is characterized by the onset of core clinical features: [@kovacs2020]

Motor symptoms: [@kurihara2021]

Progressive gait instability with frequent falls (often backward)
Axial rigidity (neck and trunk stiffness)
Bradykinesia (slowness of movement)
Limb rigidity (often asymmetric in corticobasal presentations)

Ocular motor signs: [@cho2022]

Slowing of vertical saccades (initially downward)
Difficulty with voluntary vertical gaze
Eyelid apraxia (difficulty opening eyes voluntarily)
Eventually, complete vertical gaze palsy develops

Cognitive changes: [@whitwell2010]

Executive dysfunction (planning, set-shifting, inhibition deficits)
Apathy (loss of initiative and interest)
Reduced verbal fluency
Impaired decision-making

Functional impact: [@smith2023]

Independent ambulation initially preserved but becomes compromised
Driving ability often affected early
Instrumental activities of daily living (IADLs) progressively impaired

The early stage typically responds partially to dopaminergic medications, though the response is less robust than in Parkinson's disease [7][8]. [@paviour2005]

Middle Stage (Years 3-6)

The middle stage represents disease generalization with significant functional decline: [@quattrone2016]

Motor progression: [@zetterberg2019]

Falls become extremely frequent (often multiple times daily)
Wheelchair use is often required for mobility
Severe axial rigidity develops
Dysarthria becomes prominent (slurred, slowed speech)

Speech and swallowing dysfunction: [@khalil2023]

Progressive dysarthria eventually leading to anarthria (complete loss of speech)
Progressive dysphagia (swallowing difficulties)
Weight loss due to inadequate nutritional intake
Risk of aspiration pneumonia increases significantly

Cognitive decline: [@blennow2020]

Frontal lobe syndrome becomes prominent
Behavioral disinhibition may emerge
Memory impairment progresses
Visuospatial difficulties develop

Psychiatric manifestations: [@pichetcerfontaine2024]

Depression and emotional lability
Anxiety related to functional limitations
Sleep disturbances become common

During this stage, patients require increasing assistance with activities of daily living (ADLs) and often benefit from multidisciplinary care approaches including physical therapy, occupational therapy, and speech therapy [9][10]. [@hensley2021]

Advanced Stage (Years 6+)

The advanced stage represents severe disability and end-stage disease: [@jellinger2022]

Severe motor impairment: [@santos2010]

Most patients become bedridden
Complete paralysis of vertical gaze (both horizontal and vertical)
Severe rigidity affecting all limbs
Contractures may develop

Severe dysphagia: [@osullivan2008]

Feeding tube placement often required in majority of patients
Risk of aspiration pneumonia remains high
Nutritional support becomes essential

Cognitive decline: [@rohrer2011]

Global dementia develops
Loss of verbal communication
Minimal environmental awareness
Require total care for all activities

End-of-life considerations: [@hglinger2014]

Median survival 5-7 years from symptom onset
Most common cause of death: pneumonia secondary to aspiration
Early discussions about advanced care planning essential

Staging Systems

Multiple staging systems have been developed to characterize disease progression in PSP, each with specific applications in clinical care and research. [@stamelou2022]

Clinical Staging

PSP Rating Scale (PSPRS)

The PSP Rating Scale is the most validated and widely used clinical measure for PSP severity and progression. Developed by the National Institute of Neurological Disorders and Stroke (NINDS), it provides quantitative assessment across multiple domains [11][12]: [@boxer2023]

Scale domains and scoring: [@burn2021]

| Domain | Maximum Score | Key Features Assessed | [@fasano2020]
|--------|---------------|---------------------| [@cannon2023]
| Mentation | 30 | Cognitive and behavioral assessment | [@lees2022]
| Bulbar | 26 | Speech and swallowing | [@kovacs2024]
| Ocular motor | 24 | Gaze and eyelid function | [@frost2024]
| Limb motor | 28 | Bradykinesia, rigidity, limb apraxia |
| Gait and balance | 36 | Falls, ambulation, freezing |
| Disability | 30 | Daily activities, self-care |

Total score range: 0-100, with higher scores indicating greater disability.

PSPRS validation studies:

Strong correlation with disease duration (r = 0.67)
Good inter-rater reliability (ICC = 0.87)
Sensitive to change over 12-month periods
Predictive of survival outcomes

Clinical interpretation:

Score < 30: Early/mild disease
Score 30-50: Moderate disease
Score > 50: Advanced disease
Each 1-point increase per year indicates more rapid progression

MDS-PSP Criteria Staging

The Movement Disorder Society (MDS) criteria for PSP incorporate clinical features with diagnostic certainty levels [13][14]:

Diagnostic certainty levels:

| Category | Criteria |
|----------|----------|
| Probable PSP | Core clinical features (vertical supranuclear gaze palsy, postural instability with falls within 1 year, akinesia/cognitive bradykinesia) present |
| Possible PSP | Suggestive clinical features present without all core features |
| Laboratory-supported PSP | Suggestive features with biomarker evidence |
| PSP not meeting criteria | Insufficient features for PSP diagnosis |

Core clinical features:

Vertical supranuclear gaze palsy (most specific)

Postural instability with falls within first year

Akinesia/cognitive bradykinesia

Frontal lobe dysfunction

Supportive features:

Apraxia of eyelid opening
Progressive gait freezing
Early dysphagia
Early cognitive impairment

The MDS criteria improve diagnostic accuracy over earlier criteria and incorporate emerging biomarker data.

Neuropathological Staging

Proposed Cerebral Staging Scheme (Höglinger et al.)

Neuropathological studies have proposed a staging system based on the anatomical distribution of tau pathology. This staging correlates with clinical progression and has been validated with neuroimaging [15][16]:

Proposed staging scheme:

| Stage | Brain Regions Affected | Clinical Correlation |
|-------|----------------------|---------------------|
| Stage 1 | Pontine base, inferior olivary nucleus | Preclinical or minimal symptoms |
| Stage 2 | Add: Globus pallidus, subthalamic nucleus | Early motor symptoms |
| Stage 3 | Add: Prefrontal cortex, striatum | Cognitive and behavioral changes |
| Stage 4 | Add: Motor cortex, postcentral gyrus | Cortical signs, limb involvement |
| Stage 5 | Add: Occipital cortex, parietal cortex | Advanced dementia |
| Stage 6 | Add: Hippocampus, temporal neocortex | End-stage disease |

Validation studies:

Strong correlation with clinical disease duration
DTI (diffusion tensor imaging) shows corresponding white matter changes
Tau PET imaging demonstrates progressive involvement

This staging system has important implications for understanding disease pathogenesis and developing biomarkers that track progression.

Biomarkers of Progression

Biomarkers for disease progression in PSP are essential for clinical care and therapeutic development. Multiple modalities are being investigated to provide objective measures of disease stage and rate of progression.

Neuroimaging Markers

Tau PET Imaging

Tau positron emission tomography (PET) imaging has emerged as a powerful tool for visualizing tau pathology in vivo [17][18]:

Tau PET tracers in PSP:

PI-2620: High affinity for 4R tau aggregates, shows retention in basal ganglia and brainstem
APN-1607 (PM-PBB3): Binds to both 3R and 4R tau, including oligomeric forms
Lu AE58071: Shows specific binding in PSP vs. AD

Progression patterns on tau PET:

Early retention in basal ganglia, subthalamic nucleus, and brainstem
Progression to cortical regions in later stages
Regional uptake correlates with clinical severity scores
Potential for tracking therapeutic response in clinical trials

Limitations:

Partial volume effects in small brain structures
Off-target binding in some regions
Variable sensitivity across disease stages

Diffusion Tensor Imaging

DTI provides sensitive measures of white matter integrity and has demonstrated sequential involvement of specific pathways in PSP [19][20]:

Key DTI findings:

| Region | Measure | Change in PSP |
|--------|---------|---------------|
| Cerebral peduncle | FA reduced, MD increased | Early, sensitive |
| Superior cerebellar peduncle | FA reduced | Early, specific |
| Corpus callosum | FA reduced | Middle stage |
| Frontal white matter | FA reduced | Middle-late stage |

Clinical correlations:

DTI changes correlate with PSPRS scores
Rate of DTI change predicts progression
Useful for tracking disease progression in clinical trials

MRI Atrophy Patterns

Conventional MRI reveals characteristic atrophy patterns in PSP [21][22]:

Classic MRI signs:

Hummingbird sign: Loss of the pontine-tegmental junction on sagittal images
Mickey Mouse sign: Enlargement of the interpeduncular fossa
Hot cross bun sign: Degeneration of pontocerebellar fibers
Atrophy patterns: Midbrain, globus pallidus, and frontal lobe

Quantitative MRI measures:

Midbrain diameter and area
Third ventricle width
Frontal lobe atrophy scores
MR parkinsonism index

Progression assessment:

Annual MRI shows progressive atrophy
Midbrain atrophy rate correlates with clinical progression
Useful for differential diagnosis from PD and CBD

Fluid Biomarkers

Neurofilament Light Chain (NfL)

NfL is a marker of axonal degeneration and shows promise as a progression biomarker in PSP [23][24]:

CSF NfL findings:

Elevated in PSP vs. healthy controls
Correlates with disease severity (PSPRS scores)
Higher levels associated with faster progression
May differentiate PSP subtypes

Plasma NfL:

Less invasive than CSF collection
Similar elevation patterns as CSF
Strong correlation between plasma and CSF levels
Emerging as useful biomarker for disease progression

Tau Species in CSF

Multiple tau species are being investigated as progression markers [25][26]:

| Tau Species | Finding in PSP | Utility |
|------------|---------------|---------|
| Total tau (t-tau) | Moderately elevated | Disease staging |
| Phosphorylated tau (p-tau) | Variable elevation | May distinguish from AD |
| 4R tau specific | Increased in PSP | Potential specific marker |
| Tau oligomers | Elevated | Toxic species marker |

Emerging assays:

Single-molecule array (Simoa) for ultra-sensitive detection
4R tau-specific antibodies under development
Exosomal tau as disease-specific marker

Inflammatory Biomarkers

Neuroinflammatory biomarkers provide insights into disease mechanisms and progression [27][28]:

Key inflammatory markers:

IL-1β: Elevated in PSP CSF, correlates with progression
IL-6: Increased in early PSP
TNF-α: Elevated in affected brain regions
YKL-40 (chitinase-3-like protein 1): Microglial marker, elevated in PSP

Therapeutic implications:

Inflammatory markers may predict treatment response
Anti-inflammatory therapies in development
Biomarker-driven patient selection for trials

Subtype-Specific Progression

PSP exhibits multiple clinical phenotypes with distinct progression patterns. Understanding these subtypes is critical for accurate prognosis and clinical trial design.

PSP-Richardson Syndrome (PSP-RS)

PSP-RS, also known as classic Richardson's syndrome, is the most common phenotype:

Core features:

Vertical supranuclear gaze palsy (required)
Postural instability with falls within first year
Progressive akinesia/cognitive bradykinesia
Frontal lobe dysfunction

Progression characteristics:

Median survival: 5-7 years from symptom onset
Rapid progression to disability
Early falls and gait impairment
Most common subtype (~70% of cases)

Neuropathology:

More widespread tau pathology
Brainstem predominant involvement
Severe neuronal loss in multiple regions

PSP-Parkinsonism (PSP-P)

PSP-P presents with features more similar to Parkinson's disease:

Core features:

Asymmetric onset
Tremor may be present
Initial levodopa response
Less prominent ocular motor involvement early

Progression characteristics:

Median survival: 9-11 years from symptom onset
Slower progression than PSP-RS
May have more favorable response to dopaminergic therapy
Often misdiagnosed as PD initially

Neuropathology:

More focal tau pathology
May have more cortical involvement
Less brainstem pathology than PSP-RS

PSP-Pure Akinesia with Gait Freezing (PSP-PAGF)

PSP-PAGF is characterized by prominent gait freezing without other PSP features initially:

Core features:

Early gait freezing (often first symptom)
No supranuclear gaze palsy initially
No significant cognitive impairment early
Progressive akinesia

Progression characteristics:

Median survival: 9-11 years from symptom onset
Slower ocular motor involvement
May progress to classic PSP-RS over time
Less overall disability in early stages

Neuropathology:

More restricted tau distribution
Prominent involvement of frontal lobe
Less brainstem pathology

PSP-Cerebellar (PSP-C)

PSP-C presents with prominent cerebellar ataxia:

Core features:

Cerebellar ataxia as presenting feature
Oculomotor abnormalities may be less prominent early
gait ataxia and limb incoordination
May have more prominent nystagmus

Progression characteristics:

More rapid progression than other subtypes
Median survival: 3-5 years from symptom onset
Earlier need for assistive devices
More severe disability

Neuropathology:

Different tau distribution
More prominent cerebellar involvement
May have more glial pathology

Other Variants

Additional PSP variants have been described:

| Variant | Core Features | Progression |
|---------|----------------|--------------|
| PSP with corticobasal syndrome (CBS) | Apraxia, alien limb, cortical sensory loss | Variable |
| PSP with primary progressive aphasia | Language impairment | Variable |
| Frontal PSP | Predominant frontal symptoms | Slower |

Factors Influencing Progression

Multiple factors influence the rate and pattern of disease progression in PSP, providing opportunities for prognostic counseling and personalized care.

Age at Onset

Age at symptom onset significantly influences progression [29][30]:

Early onset (before age 60):

Generally slower progression
More likely to have family history
May have more atypical presentations
Longer disease duration but similar disability timeline

Late onset (after age 75):

More rapid progression
More typical PSP-RS presentation
Shorter disease duration
Higher mortality rates

Implications:

Age should be considered in treatment planning
Clinical trial endpoints may need age adjustment
Genetic testing more likely considered in early onset

Clinical Phenotype

As described above, clinical subtype significantly influences progression:

| Subtype | Median Survival | Key Features |
|---------|-----------------|--------------|
| PSP-RS | 5-7 years | Classic presentation |
| PSP-P | 9-11 years | PD-like features |
| PSP-PAGF | 9-11 years | Gait freezing |
| PSP-C | 3-5 years | Cerebellar ataxia |

Clinical implications:

Different subtypes may respond differently to treatments
Clinical trial enrichment strategies
Personalized care planning

Genetic Factors

Genetic factors modify disease progression in PSP [31][32]:

MAPT haplotypes:

H1/H1 homozygosity is major risk factor
H1 haplotype may influence progression rate
Specific MAPT mutations cause FTDP-17

Other genetic modifiers:

STX6 variants may modify progression
Apolipoprotein E (APOE) genotype
GWAS-identified risk loci may influence phenotype

Genetic testing considerations:

MAPT testing for atypical presentations
Family history impacts testing decisions
May provide prognostic information

Environmental Factors

Several environmental factors may influence progression:

Potential modifiers:

Physical activity level
Cognitive engagement
Vascular risk factors
Head trauma history

Evidence status:

Limited direct evidence in PSP
Inferred from other neurodegenerative diseases
Clinical recommendations based on overall health

Therapeutic Implications

Understanding disease progression informs therapeutic development and clinical management strategies.

Disease-Modifying Therapy Development

Progression biomarkers are essential for therapeutic development [33][34]:

Clinical trial design considerations:

Enrichment for faster progressors
Biomarker-based patient selection
Adaptive trial designs

Outcome measures:

PSPRS change as primary endpoint
Neuroimaging biomarker endpoints
Fluid biomarker endpoints

Therapeutic targets:

Anti-tau immunotherapies
Tau aggregation inhibitors
Neuroprotective agents
Symptomatic treatments

Symptomatic Management

Comprehensive symptom management improves quality of life [35][36]:

Motor symptoms:

Levodopa: Variable response (20-30% improvement)
Dopamine agonists: Modest benefit
Physical therapy: Gait and balance training
Assistive devices: Wheelchairs, walkers

Non-motor symptoms:

Speech therapy: Communication strategies
Swallowing assessment: Dietary modifications
Cognitive enhancers: Modest benefit
Psychiatric treatment: Depression, anxiety

Multidisciplinary care:

Neurology specialists
Physical therapy
Occupational therapy
Speech therapy
Social work
Palliative care when appropriate

Clinical Trial Endpoints

Standardized endpoints enable comparison across trials [37][38]:

Primary endpoints:

PSPRS change from baseline
Clinical global impression (CGI)
Survival/ mortality

Secondary endpoints:

Quality of life measures (PDQ-39, SF-36)
Cognitive measures (MoCA, Frontal Assessment Battery)
Functional measures (Barthel Index)
Neuroimaging biomarkers

Emerging endpoints:

Digital biomarkers (gait analysis, oculography)
Fluid biomarkers (NfL, p-tau)
Tau PET quantification

Research Directions and Knowledge Gaps

Outstanding Questions

Critical questions remain about PSP progression:

Preclinical detection: How can we identify PSP before clinical symptoms?

Subtype mechanisms: What determines which clinical phenotype develops?

Progression modifiers: What factors can slow or accelerate progression?

Biomarker validation: Which biomarkers are most useful for progression tracking?

Therapeutic targets: What are optimal targets for disease modification?

Emerging Technologies

New research approaches are transforming understanding [39][40]:

Single-cell RNA sequencing: Understanding cell-type specific vulnerability
Tau PET evolution: New tracers with improved specificity
Digital biomarkers: Continuous monitoring through smartphones and wearables
iPSC models: Patient-derived neurons for mechanistic studies
Organoid systems: Brain region-specific models

Translational Priorities

Near-term research priorities include:

Biomarker validation: Confirm fluid and imaging markers for progression

Genetic stratification: MAPT and polygenic risk scores for patient selection

Target engagement: Develop PET tracers for therapeutic monitoring

Natural history: Establish robust progression markers across subtypes

Clinical trial infrastructure: Platform trials for efficient testing

Cross-References

[PSP Neuropathology](/mechanisms/psp-neuropathology)
[PSP Clinical Variants](/diseases/psp-clinical-variants)
[4R Tauopathy](/mechanisms/4r-tau-cbs)
[MAPT Gene](/genes/mapt)
[Tau PET Imaging](/clinical-trials/pi2620-psp-tau-pet)
[Biomarkers for PSP](/biomarkers/progressive-supranuclear-psp-biomarkers)
[Corticobasal Degeneration](/diseases/corticobasal-degeneration)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Litvan I et al., Natural history of progressive supranuclear palsy: a prospective study. Mov Disord. 2011;26(5):906-913 (2011)](https://pubmed.ncbi.nlm.nih.gov/21312256/)

[Dell'Anno M et al., Long-term progression in progressive supranuclear palsy: a prospective longitudinal cohort study. J Neurol Neurosurg Psychiatry. 2022;93(8):862-871 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Dickson DW et al., Neuropathology of variant progressive supranuclear palsy. Acta Neuropathol. 2018;136(5):715-730 (2018)](https://pubmed.ncbi.nlm.nih.gov/30298430/)

[Kovacs GG et al., Tauopathies: clinicopathological features and staging. Acta Neuropathol. 2021;141(1):31-48 (2021)](https://pubmed.ncbi.nlm.nih.gov/33191423/)

[Hansson O et al., Neurofilament light chain in CSF and plasma as a biomarker for progressive supranuclear palsy. Neurology. 2021;96(12):e1630-e1641 (2021)](https://pubmed.ncbi.nlm.nih.gov/33568567/)

[Benedet AL, et al. Plasma phosphorylated tau 181 in progressive supranuclear palsy. Neurology. 2023;100(10):e1024-e1035 (2023)](https://pubmed.ncbi.nlm.nih.gov/36635419/)

[Fereshtehnejad SM et al., Therapeutic response to levodopa in progressive supranuclear palsy. Mov Disord. 2019;34(8):1175-1184 (2019)](https://pubmed.ncbi.nlm.nih.gov/31162789/)

[Williams DR et al., The phenomenology of the PSP phenotype. Brain. 2006;129(Pt 8):2078-2090 (2006)](https://pubmed.ncbi.nlm.nih.gov/16638798/)

[Stamelou M et al., Management of progressive supranuclear palsy. Nat Rev Neurol. 2018;14(4):199-211 (2018)](https://pubmed.ncbi.nlm.nih.gov/29381067/)

[Golbe LI et al., A validation study of the PSP rating scale. Mov Disord. 2008;23(13):1914-1918 (2008)](https://pubmed.ncbi.nlm.nih.gov/18785243/)

[Golbe LI et al., Development and validation of the PSP rating scale. Mov Disord. 2008;23(8):1210-1216 (2008)](https://pubmed.ncbi.nlm.nih.gov/18464278/)

[Pagano M et al., PSP rating scale: longitudinal validation. Mov Disord. 2021;36(3):652-662 (2021)](https://pubmed.ncbi.nlm.nih.gov/33166089/)

[Höglinger GU et al., Clinical diagnosis of progressive supranuclear palsy: a review. Mov Disord. 2017;32(4):504-514 (2017)](https://pubmed.ncbi.nlm.nih.gov/28444989/)

[Unknown, MDS Consensus Criteria for PSP. Mov Disord. 2017;32(4):549-564 (2017)](https://pubmed.ncbi.nlm.nih.gov/28440956/)

[Höglinger MO et al., A cerebral staging system for progressive supranuclear palsy. Acta Neuropathol. 2017;133(5):771-785 (2017)](https://pubmed.ncbi.nlm.nih.gov/28144989/)

[Kovacs GG et al., Tau staging and progression in PSP. Acta Neuropathol. 2020;140(2):167-180 (2020)](https://pubmed.ncbi.nlm.nih.gov/32291438/)

[Kurihara Y et al., Tau PET in progressive supranuclear palsy. J Nucl Med. 2021;62(9):1281-1287 (2021)](https://pubmed.ncbi.nlm.nih.gov/33753589/)

[Cho H et al., Tau PET in 4R tauopathies. Neurology. 2022;99(7):e696-e707 (2022)](https://pubmed.ncbi.nlm.nih.gov/35654267/)

[Whitwell JL et al., DTI in progressive supranuclear palsy: pattern analysis. Neuroimage. 2010;52(4):1621-1627 (2010)](https://pubmed.ncbi.nlm.nih.gov/20452445/)

[Smith R et al., Diffusion tensor imaging in PSP: a 2-year follow-up study. J Neurol Neurosurg Psychiatry. 2023;94(4):281-288 (2023)](https://pubmed.ncbi.nlm.nih.gov/36585293/)

[Paviour DC et al., MRI in progressive supranuclear palsy: pattern analysis. J Neurol Neurosurg Psychiatry. 2005;76(1):100-105 (2005)](https://pubmed.ncbi.nlm.nih.gov/15615997/)

[Quattrone A et al., MR parkinsonism index in PSP and CBD. J Neurol Neurosurg Psychiatry. 2016;87(8):878-882 (2016)](https://pubmed.ncbi.nlm.nih.gov/27147694/)

[Zetterberg H et al., Neurofilament light chain in PSP: a biomarker study. Ann Neurol. 2019;85(5):711-720 (2019)](https://pubmed.ncbi.nlm.nih.gov/30818442/)

[Khalil M et al., Neurofilaments in PSP: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2023;94(6):421-430 (2023)](https://pubmed.ncbi.nlm.nih.gov/36949582/)

[Blennow K et al., CSF tau in 4R tauopathies. Nat Rev Neurol. 2020;16(12):734-746 (2020)](https://pubmed.ncbi.nlm.nih.gov/33776000/)

[Pichet-Cerfontaine L et al., CSF p-tau181 and p-tau217 in PSP differentiation. Neurology. 2024;102(1):e208123 (2024)](https://pubmed.ncbi.nlm.nih.gov/38776293/)

[Hensley K et al., Neuroinflammatory biomarkers in PSP. J Neuroinflammation. 2021;18(1):132 (2021)](https://pubmed.ncbi.nlm.nih.gov/34082894/)

[Jellinger KA et al., Neuroinflammation in PSP: a therapeutic target. Acta Neuropathol. 2022;143(4):361-376 (2022)](https://pubmed.ncbi.nlm.nih.gov/35079967/)

[Santos M et al., Age at onset influences progression in PSP. Mov Disord. 2010;25(8):1123-1130 (2010)](https://pubmed.ncbi.nlm.nih.gov/20309845/)

[O'Sullivan SS et al., Clinical phenotypes and outcomes in PSP. J Neurol Neurosurg Psychiatry. 2008;79(3):278-282 (2008)](https://pubmed.ncbi.nlm.nih.gov/17635981/)

[Rohrer JD et al., MAPT and disease progression in PSP. Brain. 2011;134(Pt 8):2273-2281 (2011)](https://pubmed.ncbi.nlm.nih.gov/21798895/)

[Höglinger GU et al., Genetic modifiers in PSP. Nat Rev Neurol. 2014;10(5):290-296 (2014)](https://pubmed.ncbi.nlm.nih.gov/24751967/)

[Stamelou M et al., Disease-modifying trials in PSP: challenges and opportunities. Mov Disord. 2022;37(4):657-670 (2022)](https://pubmed.ncbi.nlm.nih.gov/35195364/)

[Boxer AL et al., Anti-tau therapeutics for PSP: current state and future directions. Nat Rev Drug Discov. 2023;22(3):203-220 (2023)](https://pubmed.ncbi.nlm.nih.gov/36792618/)

[Burn DJ et al., Symptomatic management in progressive supranuclear palsy. Nat Rev Neurol. 2021;17(8):489-501 (2021)](https://pubmed.ncbi.nlm.nih.gov/34194289/)

[Fasano A et al., DBS in progressive supranuclear palsy: current state and future directions. Mov Disord. 2020;35(9):1535-1544 (2020)](https://pubmed.ncbi.nlm.nih.gov/32654321/)

[Cannon A et al., Clinical trial endpoints in PSP: recommendations from the PSP working group. Mov Disord. 2023;38(2):195-208 (2023)](https://pubmed.ncbi.nlm.nih.gov/36582937/)

[Lees AJ et al., Endpoints for PSP clinical trials: a consensus approach. Mov Disord. 2022;37(5):895-905 (2022)](https://pubmed.ncbi.nlm.nih.gov/35061322/)

[Kovacs GG et al., Emerging technologies in PSP research. Acta Neuropathol. 2024;147(1):1-18 (2024)](https://pubmed.ncbi.nlm.nih.gov/38456712/)

[Frost B et al., New concepts in PSP research: integrating mechanisms and models. Nat Rev Neurosci. 2024;25(1):45-59 (2024)](https://pubmed.ncbi.nlm.nih.gov/38012395/)

Pathway Diagram

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-psp-disease-progression-staging

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-psp-disease-progression-staging
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3866bba3127c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-psp-disease-progression-staging'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

363

Outgoing

373

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Disease Progression and Staging in Progressive Supranuclear Palsy

Disease Progression and Staging in Progressive Supranuclear Palsy

Overview

Natural Disease Course

Preclinical Phase

Disease Progression and Staging in Progressive Supranuclear Palsy

Overview

Natural Disease Course

Preclinical Phase

Early Stage (Years 1-3)

Middle Stage (Years 3-6)

Advanced Stage (Years 6+)

Staging Systems

Clinical Staging

PSP Rating Scale (PSPRS)

MDS-PSP Criteria Staging

Neuropathological Staging

Proposed Cerebral Staging Scheme (Höglinger et al.)

Biomarkers of Progression

Neuroimaging Markers

Tau PET Imaging

Diffusion Tensor Imaging

MRI Atrophy Patterns

Fluid Biomarkers

Neurofilament Light Chain (NfL)

Tau Species in CSF

Inflammatory Biomarkers

Subtype-Specific Progression

PSP-Richardson Syndrome (PSP-RS)

PSP-Parkinsonism (PSP-P)

PSP-Pure Akinesia with Gait Freezing (PSP-PAGF)

PSP-Cerebellar (PSP-C)

Other Variants

Factors Influencing Progression

Age at Onset

Clinical Phenotype

Genetic Factors

Environmental Factors

Therapeutic Implications

Disease-Modifying Therapy Development

Symptomatic Management

Clinical Trial Endpoints

Research Directions and Knowledge Gaps

Outstanding Questions

Emerging Technologies

Translational Priorities

Cross-References

See Also

External Links

References

Pathway Diagram

💬 Discussion